{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:46:47Z","timestamp":1774266407753,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ad.2021.08.008","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:05:32Z","timestamp":1636545932000},"page":"294-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tratamiento con inmunoglobulina intravenosa y esteroides sist\u00e9micos en pacientes con necr\u00f3lisis epid\u00e9rmica t\u00f3xica: Experiencia en un hospital en Ciudad de M\u00e9xico"],"prefix":"10.1016","volume":"113","author":[{"given":"C.A.","family":"Barrera-Ochoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marioni-Manr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Cort\u00e1zar-Azuaje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.M.","family":"Quijada-Ucelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Saba-Mussali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Vega-Memije","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2021.08.008_bib0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/pds.3937","article-title":"REACT-Lombardia study group. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: Data from the REACT registry","volume":"25","author":"Diphoorn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.ad.2021.08.008_bib0090","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol."},{"issue":"11.","key":"10.1016\/j.ad.2021.08.008_bib0095","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: A nationwide population-based study using national health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.ad.2021.08.008_bib0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: A comprehensive review and guide to therapy","volume":"14","author":"Kohanim","year":"2016","journal-title":"I Syst Dis Ocul Surf."},{"key":"10.1016\/j.ad.2021.08.008_bib0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil."},{"key":"10.1016\/j.ad.2021.08.008_bib0120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science."},{"key":"10.1016\/j.ad.2021.08.008_bib0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","article-title":"Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis","volume":"15","author":"Paquet","year":"2006","journal-title":"Exp Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.ad.2021.08.008_bib0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0145","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: Performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res."},{"key":"10.1016\/j.ad.2021.08.008_bib0150","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: A multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.08.008_bib0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/jdv.16685","article-title":"Systemic therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A SCORTEN-based systematic review and meta-analysis","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021004130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021004130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:11:49Z","timestamp":1757553109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731021004130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0001731021004130"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2021.08.008","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento con inmunoglobulina intravenosa y esteroides sist\u00e9micos en pacientes con necr\u00f3lisis epid\u00e9rmica t\u00f3xica: Experiencia en un hospital en Ciudad de M\u00e9xico","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2021.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}